Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-23-000013
Filing Date
2023-01-05
Accepted
2023-01-05 16:31:25
Documents
2
Group Members
ORBIMED ISRAEL GP LTD.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 ss1648370_sc13da.htm SC 13D/A 69873
2 JOINT FILING AGREEMENT ss1648370_ex9901.htm EX-99.1 5285
  Complete submission text file 0000947871-23-000013.txt   76868
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Subject) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-86953 | Film No.: 23511800
SIC: 2834 Pharmaceutical Preparations

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 1022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel BioFund GP Limited Partnership (Filed by) CIK: 0001569821 (see all company filings)

EIN.: 980697985 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D/A